Sheetsmartwartremoverointment

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the removal of genital warts, plantar warts, common warts, and flat warts. Common warts are characterized by their rough, "cauliflower-like" surface appearance, while plantar warts are specifically located on the bottom of the foot, presenting tenderness and disrupting the footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The product is intended for external use only. Healthcare professionals should advise patients to avoid exposure to fire and flame during use. Proper precautions should be taken to ensure safety while administering the product.

Contraindications

Use is contraindicated in the following situations:

• Patients experiencing chest pain, rapid heartbeat, faintness, or dizziness.

• Patients with sudden, unexplained weight gain.

• Patients with swelling of the hands or feet.

• Patients exhibiting scalp irritation or redness.

• Patients with unwanted facial hair growth.

• Patients who do not observe hair regrowth within 4 months of use.

• Pregnant or breastfeeding individuals, due to potential harm.

• Application on broken or irritated scalp is contraindicated.

Warnings and Precautions

For external use only, this product must be handled with caution. It is imperative to keep it away from fire and flame to prevent any hazardous incidents.

Healthcare professionals should advise patients to discontinue use and seek medical attention if any of the following symptoms occur: chest pain, rapid heartbeat, faintness, or dizziness. Additionally, patients should be instructed to stop use if they experience sudden, unexplained weight gain, swelling of the hands or feet, scalp irritation or redness, unwanted facial hair growth, or if there is no observable hair regrowth after four months of treatment.

This product may pose risks if used during pregnancy or while breastfeeding; therefore, it is essential to counsel patients regarding these potential hazards. Furthermore, it should be kept out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Patients should also be advised to cease use if the scalp is broken or irritated, as this may exacerbate adverse effects. Regular monitoring of the scalp condition and any unusual symptoms is recommended to ensure safe use of the product.

Side Effects

Patients should be aware that the product is for external use only and must be kept away from fire and flame to prevent serious hazards. In the event of broken or irritated scalp, it is advised to discontinue use immediately to avoid exacerbating the condition.

These precautions are essential to ensure the safety and well-being of patients using the product.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified in the available data. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Sheetsmartwartremoverointment (sheetsmart wart remover ointment). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Use of this medication during pregnancy may pose risks to the developing fetus. Animal studies and clinical data suggest potential harm when administered to pregnant patients. Therefore, it is recommended that this medication be avoided in women who are pregnant or planning to become pregnant. Additionally, caution should be exercised in breastfeeding patients, as the medication may also be harmful during lactation. Healthcare professionals should carefully weigh the benefits and risks before prescribing this medication to women of childbearing potential.

Lactation

Lactating mothers should be aware that the use of this medication may be harmful during breastfeeding. There is insufficient data regarding the excretion of this drug in human breast milk and its potential effects on breastfed infants. Therefore, caution is advised when considering the use of this medication in lactating individuals. It is recommended that healthcare professionals evaluate the risks and benefits before prescribing this medication to nursing mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, the following management procedures should be considered:

1. Assessment: Conduct a thorough assessment of the patient's clinical status, including vital signs and level of consciousness.

2. Supportive Care: Provide supportive care as needed, which may include airway management, oxygen supplementation, and intravenous fluids.

3. Consultation: Engage with a poison control center or a medical toxicologist for guidance on specific interventions and antidotes, if applicable.

4. Documentation: Document all findings, interventions, and the patient's response to treatment meticulously.

Healthcare professionals should remain vigilant and prepared to implement appropriate measures in the event of an overdose, even in the absence of specific overdosage data.

Nonclinical Toxicology

May be harmful if used during pregnancy or while breastfeeding. No non-teratogenic effects have been specified. There are no additional details provided regarding nonclinical toxicology or animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children. Instruct patients that if the medication is swallowed, they should seek medical help or contact a Poison Control Center immediately at 1-800-222-1222.

Additionally, it is important to inform patients that the medication may be harmful if used during pregnancy or while breastfeeding. Providers should encourage patients to discuss any potential risks with their healthcare provider before using the medication in these circumstances.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It should be stored at room temperature, ensuring that it is kept away from fire and flame to maintain safety. Additionally, it is crucial to keep the product out of reach of children to prevent accidental ingestion. Once opened, the product must be discarded to ensure proper safety and efficacy.

Additional Clinical Information

The product is administered cutaneously, with the recommended frequency being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. Clinicians should advise patients to keep the product out of reach of children. In the event of accidental ingestion, patients should seek medical assistance or contact a Poison Control Center immediately at 1-800-222-1222.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Sheetsmartwartremoverointment, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)